Procter & Gamble

Procter & Gamble closed May 12, 2026 at $143.33 — just 4% above the 52-week low of $137.62 and 16% below the October 2025 peak of $171. The $334B market cap puts P&G as the 9th-largest US consumer staples company. The 2026 thesis is a quality-business-at-cheap-quality-price setup: P&G has compressed from forward P/E 26× (mid-2024) to 20.2× (May 2026) on three worries — GLP-1 drug headwinds on the snack/food adjacencies, China consumer weakness on SK-II/premium-beauty, and US private-label-trade-down across grocery categories. All three are real concerns, but none is structurally devastating.

Q3/FY2026 (released April 18, 2026) showed the underlying business is intact. Organic sales: +3.4% (in-line with the 3–5% long-term target), with the breakdown of +1.8% volume and +1.6% price/mix. The improvement: volume turned positive after four quarters of negative-to-flat. Beauty +4.2%, Grooming +6.1%, Health Care +4.8%, Fabric & Home Care +2.9%, Baby/Feminine/Family Care -0.8%. Five of six segments in growth territory. Operating margin: 23.4% (up 60 bps YoY). Free cash flow: $4.1B in the quarter.

The April 2026 dividend hike to $1.0568 quarterly marked the 68th consecutive annual dividend increase — the longest streak in the S&P 500 (only American States Water Company at 70+ years has a longer streak among public companies overall). The yield of 2.97% is near the 5-year peak. Combined with $9–$10B annual buyback, total capital return runs at 5.5–6% — a baseline floor for what is otherwise a low-single-digit-volume-growth business.

P&G's institutional ownership is among the most stable in the S&P 500. Vanguard 8.5%, BlackRock 6.8%, State Street 4.1% — the passive complex. Active managers tilt toward income-and-quality: Capital Group 1.9%, Wellington 1.6%. The notable buyer in 2026: Akre Capital initiated a 1.2M-share position in Q1/2026, citing 'classic Akre setup of high-ROIC compounder at multi-year low valuation.' Generation Investment Management added 800,000 shares in March 2026.

Berkshire Hathaway sold its small P&G position in 2014 — Buffett's view at the time was P&G was 'too diversified to manage well at scale.' This 12-year-old position was the wrong call: P&G has compounded ~10% annually since (including dividends), comfortably beating the S&P 500 over the same period. The Berkshire-no-position is not a directional read.

Insider activity (Form 4): CEO Jon Moeller sold 75,000 shares in February 2026 at $165 (10b5-1 routine). CFO Andre Schulten sold 28,000 shares. The notable absence of insider activity at sub-$145 — there have been no insider buys despite the 16% drawdown from peak. The lack of insider buying is the cleanest bearish signal in the data — but it is also typical for P&G, where senior officers historically buy only during 2008-style crises.

Procter & Gamble trades at a forward P/E of 20.2, EV/EBITDA of 14.6, and free-cash-flow yield of 4.6% as of May 2026. Comparable consumer-staples peers — Coca-Cola (forward P/E 22.4), PepsiCo (forward P/E 18.8), Colgate-Palmolive (forward P/E 22.0), Unilever (forward P/E 17.5) — show P&G trading roughly at peer-average despite its superior 68-year dividend track record. The discount to PG's own 5-year median (25×) is the more meaningful comparison. Wall Street median price target $163.77 (14% upside), with dispersion from $140 (Bernstein, GLP-1 + China bear) to $192 (RBC Capital, multiple-recovery bull). Sum-of-the-parts: Beauty at $35/share, Grooming at $20/share, Health Care at $25/share, Fabric & Home Care at $40/share, Baby/Feminine/Family Care at $25/share — total $145/share intrinsic, essentially current price. The 2.97% dividend + ~3% buyback yield = 6% baseline return; multiple reversion to 25× is the upside scenario.

1. July 30, 2026: Q4/FY2026 earnings (FY-end) — volume growth sustainability and SK-II China trajectory are the key prints
2. Autumn 2026: FY2027 guidance — management organic sales guide of 4–5% would signal confidence; 2–3% would confirm bear case
3. Q4/2026: GLP-1 prescription-growth Q3 data — current 14M user count vs 18M consensus is the key telegraph for category headwind sizing

Procter & Gamble at $143 is one of the cleanest 'quality-at-cheap-quality-price' setups currently available in mega-cap. The 68-year dividend track record alone is a structural moat that no other US public company matches. The forward P/E of 20.2 is 20% below the 5-year median, reflecting GLP-1 and China worries that are real but not structurally devastating. The volume-growth inflection in Q3/FY2026 is the key fundamental signal — if Q4 confirms the positive volume trend, the multiple should rerate toward 23–25×. My add-trigger is at current price ($143) for income-focused portfolios; for total-return-focused portfolios, I would wait for sub-$135 (forward P/E sub-19×) which would put PG in the 95th-percentile-cheap territory. A boring stock at a boring price with reliable compounding — exactly the kind of position that quietly drives 8–10% annualized returns over 10 years.